恩华药业：获得右酮洛芬氨丁三醇注射液的药品注册证书

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its injectable drug, Ketorolac Tromethamine, which is a non-steroidal anti-inflammatory drug (NSAID) used for acute moderate to severe postoperative pain in adults who cannot take oral medication. This marks the company's first injectable NSAID for perioperative use, and its market launch is expected to positively impact the company's future performance [1]. Group 1 - The drug is classified as a non-steroidal anti-inflammatory analgesic and serves as an adjunct to opioid analgesics [1]. - The approval signifies a strategic expansion in the company's product offerings, particularly in the perioperative pain management segment [1]. - The introduction of this drug is anticipated to enhance the company's revenue and overall market position [1].